Nano Letters · 2024 · 56 citations · 40 references
Life SciencesBiotechnologyMolecular BiologyBiosensorsMolecular DiagnosticsMolecular OncologyCancer Molecular DiagnosticsCrispr-cas SystemsLiquid BiopsyNucleic Acid BiosensorsPoint-of-care BiosensingQuantum Dots In BiologyBiomolecular DetectionClinical Diagnostics AptasensorsCrispr-based BiosensorsDirect DetectionDirect MeasurementEarly DiagnosisLiquid Biopsy DetectionQuantum Dot Biosensors
Accurate and sensitive analysis of circulating tumor cells (CTCs) in human blood provides a non-invasive approach for the evaluation of cancer metastasis and early cancer diagnosis. Herein, we demonstrate the controllable assembly of a quantum dot (QD)-based aptasensor guided by CRISPR/Cas12a for direct measurement of CTCs in human blood. We introduce a magnetic bead@activator/recognizer duplex core–shell structure to construct a multifunctional platform for the capture and direct detection of CTCs in human blood, without the need for additional CTC release and re-identification steps. Notably, the introduction of magnetic separation ensures that only a target-induced free activator can initiate the downstream catalysis, efficiently avoiding the undesired catalysis triggered by inappropriate recognition of the activator/recognizer duplex structure by crRNAs. This aptasensor achieves high CTC-capture efficiency (82.72%) and sensitive detection of CTCs with a limit of detection of 2 cells mL –1 in human blood, holding great promise for the liquid biopsy of cancers.
40
CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity
Janice S. Chen, Enbo Ma, Lucas B. Harrington et al. · Science · 2018 · 4.4K citations
Cancer biomarker detection: recent achievements and challenges
Li Wu, Xiaogang Qu · Chemical Society Reviews · 2015 · 1.2K citations
Medicine, Biochemistry, Oncology +16